Five‐year outcomes with self‐expanding versus balloon‐expandable TAVI in patients with left ventricular systolic dysfunction - 08/12/24
ABSTRACT |
Background |
The importance of transcatheter heart valve (THV) design on clinical outcome in patients with aortic stenosis (AS) and left ventricular (LV) systolic dysfunction remains unknown.
Objectives |
We aimed to compare 5-year outcomes of patients with severe AS and reduced LV ejection fraction (LVEF), undergoing transcatheter aortic valve implantation (TAVI) with balloon-expandable vs. self-expanding THVs.
Methods |
In a retrospective analysis from the Bern TAVI registry, patients with LVEF <50% who underwent TAVI with either balloon-expandable or self-expanding THVs were included. A 1:1 propensity-score matching was performed to account for baseline differences between groups.
Results |
A total of 759 patients were included between August 2007 and December 2022, and propensity-score matching resulted in 134 pairs. Technical success was achieved in over 85% of patients, and was similar in both groups. Self-expanding THVs were associated with a lower mean transvalvular gradient (7.1 ± 3.7 mmHg vs. 9.9 ± 4.3 mmHg; P < .001) and a higher incidence of ≥mild-to-moderate paravalvular regurgitation (36.3% vs. 11.3%; P < .001) compared to balloon-expandable THVs. At 5 years, patients treated with a self-expanding THV had higher all-cause mortality than those with a balloon-expandable THV (67.8% vs. 55.8%, HRadjusted: 1.44; 95% CI: 1.02-2.03; P = .037). There were no significant differences in other clinical outcomes up to 5 years between groups.
Conclusions |
In the setting of LV systolic dysfunction, patients treated with a self-expanding THV had higher risk of 5-year mortality compared to patients treated with a balloon-expandable THV.
Clinical Trial Registration |
www.clinicaltrials.gov. NCT01368250.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Plan
Vol 280
P. 18-29 - février 2025 Retour au numéro
Article précédent
- Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications
- Navid Noory, Oscar Westin, Mathew S. Maurer, Emil Fosbøl, Finn Gustafsson
- Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
- Alexander C. Fanaroff, Amit N. Vora, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger, Shaun G. Goodman, Ronald Aronson, Stephan Windecker, John H. Alexander, Renato D. Lopes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?